Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer

Michael P. Lux; Andreas D. Hartkopf; Tanja N. Fehm; Manfred Welslau; Volkmar Müller; Florian Schütz; Peter A. Fasching; Wolfgang Janni; Isabell Witzel; Christoph Thomssen; Milena Beierlein; Erik Belleville; Michael Untch; Marc Thill; Hans Tesch; Nina Ditsch; Bahriye Aktas; Maggie Banys-Paluchowski; Cornelia Kolberg-Liedtke; Achim Wöckel; Hans-Christian Kolberg; Nadia Harbeck; Rupert Bartsch; Andreas Schneeweiss; Johannes Ettl; Rachel Würstlein; David Krug; Florin-Andrei Taran; Diana Lüftner; Elmar Stickeler

doi:10.1055/a-2074-0125

Geburtshilfe und Frauenheilkunde, Table of Contents

CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2023; 83(06): 664-672
DOI: 10.1055/a-2074-0125

GebFra Science

Review

Update Mammakarzinom 2023 Teil 2 – Brustkrebs in fortgeschrittenen Krankheitsstadien

Article in several languages: English | deutsch

Authors

Michael P. Lux

¹Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Paderborn, Germany
Andreas D. Hartkopf

²Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany (Ringgold ID: RIN27197)
Tanja N. Fehm

³Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
Manfred Welslau

⁴Onkologie Aschaffenburg, Aschaffenburg, Germany
Volkmar Müller

⁵Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
Florian Schütz

⁶Gynäkologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, Germany (Ringgold ID: RIN123168)
Peter A. Fasching

⁷Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany (Ringgold ID: RIN207200)
Wolfgang Janni

²Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany (Ringgold ID: RIN27197)
Isabell Witzel

⁸Klinik für Gynäkologie, Universitätsspital Zürich, Zürich, Switzerland (Ringgold ID: RIN31005)
Christoph Thomssen

⁹Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany (Ringgold ID: RIN9176)
Milena Beierlein

⁷Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany (Ringgold ID: RIN207200)
Erik Belleville

¹⁰ClinSol GmbH & Co KG, Würzburg, Germany
Michael Untch

¹¹Clinic for Gynecology and Obstetrics, Breast Cancer Center, Gynecologic Oncology Center, Helios Klinikum Berlin Buch, Berlin, Germany (Ringgold ID: RIN62473)
Marc Thill

¹²Department of Gynecology and Gynecological Oncology, Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany (Ringgold ID: RIN84491)
Hans Tesch

¹³Oncology Practice at Bethanien Hospital, Frankfurt am Main, Germany
Nina Ditsch

¹⁴Department of Gynecology and Obstetrics, University Hospital Augsburg, Augsburg, Germany (Ringgold ID: RIN39694)
Bahriye Aktas

¹⁵Department of Gynecology, University of Leipzig Medical Center, Leipzig, Germany
Maggie Banys-Paluchowski

¹⁶Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
Cornelia Kolberg-Liedtke

¹⁷Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany (Ringgold ID: RIN39081)
Achim Wöckel

¹⁸Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany
Hans-Christian Kolberg

¹⁹Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany
Nadia Harbeck

²⁰Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, München, Germany
Rupert Bartsch

²¹Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria
Andreas Schneeweiss

²²National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany
Johannes Ettl

²³Klinik für Frauenheilkunde und Gynäkologie, Klinikum Kempten, Klinikverbund Allgäu, Kempten, Germany
Rachel Würstlein

²⁰Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, München, Germany
David Krug

²⁴Klinik für Strahlentherapie, Universitätsklinkum Schleswig-Holstein, Campus Kiel, Kiel, Germany (Ringgold ID: RIN15056)
Florin-Andrei Taran

²⁵Department of Gynecology and Obstetrics, University Hospital Freiburg, Freiburg, Germany
Diana Lüftner

²⁶Medical University of Brandenburg Theodor-Fontane, Immanuel Hospital Märkische Schweiz, Buckow, Germany
Elmar Stickeler

²⁷Department of Obstetrics and Gynecology, Center for Integrated Oncology (CIO Aachen, Bonn, Cologne, Düsseldorf), University Hospital of RWTH Aachen, Aachen, Germany

Abstract

Zusammenfassung

Eine Reihe von neuen Therapien hat in den letzten Jahren die Fortschritte in der Behandlung von Patientinnen mit fortgeschrittenem Mammakarzinom bestimmt. Diese Substanzen sind hauptsächlich die CDK4/6-Inhibitoren und weitere Substanzen, welche die endokrine Resistenz überwinden können, die oralen selektiven Östrogenrezeptor-Degradierer, die Antikörper-Medikament Konjugate (ADCs) und die PARP-Inhibitoren. In dieser Übersichtsarbeit werden die neuesten Studienergebnisse zusammengefasst und bewertet, die in den letzten Monaten veröffentlicht worden sind. Dies beinhaltet die Gesamtüberlebensdaten der Destiny-Breast03-Studie, die erste Analyse der CAPItello-291-Studie, den Vergleich einer CDK4/6-Inhibitor-Therapie mit Chemotherapie in der ersten Therapielinie (RIGHT Choice-Studie), die erste Analyse der Destiny-Breast02-Studie im Therapie-Setting nach T-DM1-Therapie und die erste Analyse der Serena-2-Studie.

Die meisten dieser Studien haben das Potenzial, die Therapielandschaft für Patientinnen mit fortgeschrittenem Mammakarzinom deutlich zu verändern, und zeigen, dass die Entwicklung neuer Therapien mit einer nach wie vor hohen Geschwindigkeit immer neue Ergebnisse produziert.

Schlüsselwörter

Brustkrebs - metastatisch - endokrine Therapie - Antikörper-Medikament-Konjugat - Chemotherapie

Full Text

References

References/Literatur
1 Ditsch N, Kolberg-Liedtke C, Friedrich M. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. Breast Care (Basel) 2021; 16: 214-227
2 Cardoso F, Paluch-Shimon S, Senkus E. et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020; 31: 1623-1649
3 Schneeweiss A, Ettl J, Luftner D. et al. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer – Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast 2020; 54: 88-95
4 Hartkopf AD, Huober J, Volz B. et al. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors – Data from the German PRAEGNANT breast cancer registry. Breast 2018; 37: 42-51
5 Lobbezoo DJ, van Kampen RJ, Voogd AC. et al. In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Ann Oncol 2016; 27: 256-262
6 Engler T, Fasching PA, Luftner D. et al. Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT. Geburtshilfe Frauenheilkd 2022; 82: 1055-1067
7 Jackisch C, Brucker C, Decker T. et al. Abstract P4–01–01: RIBANNA 5th interim analysis: Matched-pair analysis of progression-free survival (PFS) across treatment cohorts and comparison of frontline ribociclib + endocrine therapy PFS data from RIBANNA vs MONALEESA trials, in HR+, HER2– ABC. San Antonio Breast Cancer Symposium 2022. Cancer Res 2023; 83 (Suppl. 5) P4–01–01
8 Lu YS, Bin Mohd Mahidin EI, Azim H. et al. Abstract GS1–10: Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2− Advanced Breast Cancer Treated With Ribociclib + Endocrine Therapy vs Physician’s Choice Combination Chemotherapy. San Antonio Breast Cancer Symposium 2022. Cancer Res 2023; 83 (Suppl. 5) GS1–10
9 Rugo HS, Bardia A, Marmé F. et al. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2−) advanced breast cancer. J Clin Oncol 2022; 40: LBA1001
10 Modi S, Saura C, Yamashita T. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med 2020; 382: 610-621
11 Hurvitz SA, Tolaney SM, Punie K. et al. Abstract GS3–06: Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. San Antonio Breast Cancer Symposium 2020. Cancer Res 2021; 81 (Suppl. 4) GS3–06
12 Rugo HS, Bardia A, Marmé F. et al. Abstract GS1–11: Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC): Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients (Pts) With HR+/HER2– Metastatic Breast Cancer (mBC). San Antonio Breast Cancer Symposium 2022. Cancer Res 2023; 83 (Suppl. 5) GS1–11
13 Bidard FC, Kaklamani VG, Neven P. et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol 2022; 40: 3246-3256
14 Bardia A, Neven P, Streich G. et al. Abstract GS2–02: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2− advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial. San Antonio Breast Cancer Symposium 2021. Cancer Res 2022; 82 (Suppl. 4) GS2–02
15 Tolaney SM, Chan A, Petrakova K. et al. AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC). Ann Oncol 2022; 33 (Suppl. 7) S80-S121
16 Jimenez MM, Lim E, Gregor MCM. et al. Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study. Ann Oncol 2022; 33 (Suppl. 7) S808-S869
17 Luftner D, Lux MP, Fehm TN. et al. Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer. Geburtshilfe Frauenheilkd 2023; 83: 299-309
18 Aktas B, Fehm TN, Welslau M. et al. Update Breast Cancer 2022 Part 4 – Advanced-Stage Breast Cancer. Geburtshilfe Frauenheilkd 2022; 82: 922-931
19 U.S. Department of Health and Human Services Food and Drug Administration (FDA). Highlights of Prescribing Information Orserdu. 2023 Accessed April 11, 2023 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf
20 Oliveira M, Pominchuck D, Nowecki Z. et al. Abstract GS3–02: GS3–02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial. Cancer Res 2023; 83: GS3-02
21 clinicaltrials.gov. Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (SERENA-6). 2021 Accessed October 24, 2021 at: https://clinicaltrials.gov/ct2/show/NCT04964934
22 Snyder LB, Flanagan JJ, Qian Y. et al. Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer. Cancer Res 2021; 81: 44
23 Schott AF, Hurvitz S, Ma C. et al. Abstract GS3–03: GS3–03 ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study. Cancer Res 2023; 83: GS3–03
24 Fasching PA, Clifton K, Katashvili Z. et al. 154TiP TACTIVE-N: Open-label, randomized, noncomparative neoadjuvant phase 2 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal women with ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer. ESMO Open 2023; 8 (Suppl. 4) 101493
25 Clinicaltrials.gov. A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery. 2023 Accessed April 11, 2023 at: https://clinicaltrials.gov/ct2/show/NCT05549505
26 Clinicaltrials.gov. ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer. 2023 Accessed April 11, 2023 at: https://clinicaltrials.gov/ct2/show/NCT05501769
27 Turner N, Oliveira M, Howell SJ. et al. Abstract GS3–04: GS3–04 Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial. Cancer Res 2023; 83: GS3–04
28 Alves CL, Ditzel HJ. Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer. Int J Mol Sci 2023; 24: 4522
29 Howell SJ, Casbard A, Carucci M. et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol 2022; 23: 851-864
30 Cortes J, Kim SB, Chung WP. et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med 2022; 386: 1143-1154
31 Hurvitz S, Hegg R, Chung W-P. et al. Abstract GS2–02: GS2–02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03. Cancer Res 2023; 83: GS2-02
32 Hurvitz SA, Hegg R, Chung WP. et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 2023; 401: 105-117
33 Krop I, Park YH, Kim S-B. et al. Abstract GS2–01: GS2–01 Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02. Cancer Res 2023; 83: GS2–01
34 clinicaltrials.gov. Comprehensive Analysis of Spatial, Temporal and Molecular Patters of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients (CAPTOR-BC). 2022 Accessed July 16, 2022 at: https://clinicaltrials.gov/ct2/show/NCT05452213
35 Fasching PA. CAPTOR-BC: Gemeinsam Forschen für eine individualisierte Ribociclib-Therapie. Senologiekongress 2022. 2022 Accessed June 26, 2022 at: https://www.senologiekongress.de/xconfig/upload/files/Programme/Seno2022_Programm.pdf
36 clinicaltrials.gov. Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management (MINERVA). 2022 Accessed June 26, 2022 at: https://clinicaltrials.gov/ct2/show/NCT05362760